Drugs / SURF-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04324359 | Mar → Nov 2020 | — | Surface Ophthalmics, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-01-21 | Surface Ophthalmics, Inc. | Results Surface Ophthalmics Announces Positive Top-Line Results from Phase II Trial for SURF-201 (Betamethasone 0.2% in Klarity® vehicle) for the Treatment of Post-Cataract Surgery Pain and Inflammation surfaceophthalmics.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-01-21 | Surface Ophthalmics, Inc. | Surface Ophthalmics Announces Positive Top-Line Results from Phase II Trial for SURF-201 (Betamethasone 0.2% in Klarity® vehicle) for the Treatment of Post-Cataract Surgery Pain and Inflammation surfaceophthalmics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SURF-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04324359 ↗ |
| Route | Topical | “0.2% topical preservative-free corticosteroid solution (0.2% betamethasone sodium phosphate)” NCT04324359 ↗ |